You just read:

Mundipharma EDO GmbH Announces FDA Investigational New Drug Approval of its First Anti-Cancer Compound, EDO-S101, for the Treatment of Patients with Relapsed/Refractory Haematologic Malignancies and Solid Tumours

News provided by

Mundipharma EDO GmbH

31 Jul, 2015, 13:02 BST